Simulations Plus Announces Quarterly Cash Dividend Increase

Company declares increased cash dividend of $0.03 per share

Business Wire

LANCASTER, Calif.--(BUSINESS WIRE)--

Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a cash dividend in May.

The Board of Directors declared its next ongoing quarterly cash dividend of $0.03 per share, an increase of $0.01 per share over the $0.02 per share that was planned after the accelerated dividend distribution of $0.03 per share for the expected May, August, and November 2013 distributions. This dividend will be distributed on Friday, May 10, 2013, for shareholders of record as of Tuesday, May 7, 2013.

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “The board has decided to increase the dividend to shareholders as a result of our excellent financial performance during the second fiscal quarter of fiscal year 2013, as reported in our 10-Q filed on April 10, 2013. We generated more than one million dollars in net income in the second quarter, and this dividend increase amounts to about $160,000.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added, “The Board of Directors has demonstrated that it believes in rewarding our loyal shareholders by returning a portion of our excess cash in the form of dividends. As our financial performance improves, the board will consider further increases.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. We also provide a productivity tool called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

Contact:
Simulations Plus Investor Relations
Ms. Renée Bouché, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com
View Comments